Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.07 -0.20 (-0.38%)
Streaming Delayed Price Updated: 2:38 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
31 32 Next >
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection
Via Benzinga
Sanofi (SNY) Q4 2022 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Earnings Outlook For Sanofi
Via Benzinga
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
7 Blue-Chip Stocks to Buy for Quality-Focused Investors
With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy. 
Via InvestorPlace
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price... 
Via Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each... 
Via Benzinga
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Via Benzinga
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday
With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week
The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors... 
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs. 
Via InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all... 
Via Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Could This Vaccine Become Sanofi's Latest Blockbuster?
This vaccine candidate could be approved in newborns and infants later this year. 
Via The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception. 
Via InvestorPlace
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.